Developer docs
API playgroundTry for free, no card

Search company profiles

IMVARIA

Full company profile

uuid0006cvf

Namestring
IMVARIA
Legal namestring
IMVARIA Inc.
Websiteurl
imvaria.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

IMVARIA Inc. is a Berkeley, California-based software-as-medical-device (SaMD) company founded in 2019 that commercializes AI-driven digital biomarker diagnostics for serious lung disease. The company operates a centralized, cloud-based Digital Biomarker Lab—functionally analogous to a specialty CLIA lab but analyzing imaging and clinical data rather than biospecimens—where clinicians submit CT scans and clinical information for AI analysis and receive reports within minutes. IMVARIA is ISO 13485 certified and HIPAA compliant, and serves pulmonologists, health systems, life sciences companies, and patients with suspected interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and lung cancer.

The company's product portfolio centers on three AI diagnostic tools. Fibresolve, the lead product, received FDA De Novo marketing authorization in January 2024 as the first FDA-authorized diagnostic of any type in lung fibrosis, and the first Breakthrough-Designated AI diagnostic with simultaneously adopted AMA Category III CPT billing code (0880T). ScreenDx received FDA 510(k) clearance in January 2025 as the first AI technology authorized to assess interstitial lung findings compatible with ILD. Bronchosolve, an investigational non-invasive lung cancer diagnostic, met primary endpoints in the pivotal VIRTUAL-BRONCH study in October 2025 and is advancing toward FDA submission. The underlying platform combines computer vision over CT imaging with multi-modal clinical data (text and structured values) to produce diagnostic subtype classifications and mortality predictions, trained on thousands of tissue-pathology-confirmed cases and augmented by a data collaboration with Mayo Clinic Platform.

IMVARIA generates revenue primarily through transaction-based diagnostic testing fees billable under CPT 0880T, complemented by professional services revenue from biopharma and clinical trial sponsors that use the platform for risk stratification and trial enrollment. Go-to-market combines direct enterprise sales to pulmonologists and health systems, channel partnerships (Medical Horizons for MENA, Viz.ai for U.S. health system distribution), and conference-driven clinical engagement (ATS, CHEST). The company has raised strategic capital from InHealth Ventures, Labcorp Venture Fund, Cedar Crest Holdings, Creative Ventures, and Meridian Street Capital, and was awarded a Phase I NIH SBIR grant to extend the platform into oncology.

Short descriptiontext

IMVARIA is a Berkeley-based SaMD company that uses AI to analyze CT scans and clinical data for non-invasive diagnosis of interstitial lung disease, idiopathic pulmonary fibrosis, and lung cancer, serving pulmonologists, health systems, and biopharma clients through its FDA-authorized Fibresolve, ScreenDx, and investigational Bronchosolve products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI diagnostic services, lung disease diagnostics, digital biomarker platform, medical imaging AI, clinical decision support
Industry5 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAKANAF
Interstitial Lung Disease (ILD) & Pulmonary Fibrosis Care
SECONDARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
SECONDARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
AI Medical Imaging Diagnostics
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Services
TypeTransaction Fee
Description

IMVARIA generates revenue through its AI-powered diagnostic testing services. Clinicians order Fibresolve and ScreenDx tests through IMVARIA's centralized service, submitting CT scans and clinical data for AI analysis. Results are returned to the ordering clinician. The service is billable using Category III CPT code 0880T for test result interpretation, making it practical for clinicians to incorporate into medical practice. The company works with insurance companies and has financial assistance programs for individuals.

imvaria.com
2Life Sciences / Clinical Trial Services
TypeProfessional Services
Description

IMVARIA offers its AI biomarker technology to biopharma partners and clinical trialists for optimizing study enrollment, risk-stratifying patients at trial enrollment, and developing predictions for treatment response. This represents a B2B revenue stream serving the pharmaceutical and clinical research market.

imvaria.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Fibresolve diagnostic test for ILD/IPF assessment
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Fibresolve is prescription-only and is a billable diagnostic service. The company has Category III CPT code 0880T for test result interpretation. Insurance coverage varies, and the company offers financial assistance programs for eligible individuals. Cost savings per test are expected to save thousands of dollars per person compared to invasive procedures.

imvaria.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Fibresolve
Description

FDA-authorized AI diagnostic service for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) assessment using non-invasive CT scan analysis

imvaria.com
+3 more records
Core offering1 text field

IMVARIA provides AI-driven digital biomarker diagnostic services that analyze lung CT imaging and clinical data through a centralized cloud-based Digital Biomarker Lab. Its commercial products include Fibresolve (FDA De Novo authorized for adjunctive diagnosis of ILD/IPF), ScreenDx (FDA 510(k) cleared for automated ILD screening), and the investigational Bronchosolve (non-invasive pulmonary nodule/lung cancer assessment). Clinicians and health systems submit cases and receive AI-generated diagnostic subtype classifications in minutes, billable under Category III CPT code 0880T.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IPF diagnoses increased by >3x in challenging ILD and IPF cases in the pre-invasive setting
+3 more records
Product overview1 text field

IMVARIA is a Software-as-Medical-Device (SaMD) company offering AI-driven digital biomarker solutions through a centralized diagnostic service model. The core product portfolio includes three distinct AI diagnostic tools: Fibresolve (FDA De Novo authorized, January 2024) for adjunctive diagnosis of ILD and IPF; ScreenDx (FDA 510(k) cleared, January 2025) for automated ILD screening; and Bronchosolve (investigational, pivotal study completed October 2025) for lung cancer diagnosis in suspicious pulmonary nodules. All products analyze CT imaging data using proprietary machine learning algorithms without requiring invasive procedures. Clinicians access these services through IMVARIA's centralized cloud-based AI Lab by submitting cases via a web order portal, with results returned within minutes. The platform also includes a financial assistance program and Category III CPT billing codes for reimbursement.

Product and service4 records
1Fibresolve
CategoryAI Diagnostic Software (SaMD)
Description

FDA-authorized AI diagnostic service that uses fully automated machine learning and non-invasive CT scans of the lungs to provide diagnostic subtype classification of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), serving as an adjunct to clinicians prior to invasive testing.

2ScreenDx
CategoryAI Diagnostic Software (SaMD)
Description

FDA 510(k)-cleared AI-powered screening algorithm that automatically assesses CT scans for interstitial lung findings compatible with ILD, operating as a background-only technology to enhance referral workflows without requiring technologist operation.

3Bronchosolve
CategoryAI Diagnostic Software (SaMD) — Investigational
Description

Investigational AI-powered diagnostic solution for the assessment of suspicious pulmonary nodules and non-invasive lung cancer diagnosis; a fully automated end-to-end platform designed for improved classification of indeterminate lung nodules.

4AI Lab (Digital Biomarker Lab)
CategoryDiagnostic Platform / Cloud Lab Service
Description

Centralized, cloud-based digital lab operating like a specialty CLIA lab but handling data rather than physical samples; clinicians and biopharma clients transmit cases and receive AI analysis reports in minutes, supporting multiple imaging modalities (CT, MRI) and data types under ISO 13485 quality compliance.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-18
Description

IMVARIA partnered with Viz.ai, the leader in AI-powered disease detection and care coordination, in November 2025. This collaboration expands Viz.ai's pulmonary portfolio and introduces new AI capabilities that can assess for interstitial lung findings compatible with ILD. Viz.ai has existing relationships with health systems using its care coordination software.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-10
Description

IMVARIA announced a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy, to expand presence in the MENA (Middle East and North Africa) region. Medical Horizons' extensive sales network and expertise in cloud-based healthcare solutions provides a strong foundation for accelerating adoption of IMVARIA's technology among pulmonologists. The company has a proven track record with installations at renowned centers including Campus Biomedico Roma, Meyer Labs Florence, Sant' Andrea Roma, and Gruppo Multimedia Milano.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

IMVARIA entered into a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer. The collaboration brings together IMVARIA's engineering expertise in digital biomarkers with Mayo Clinic's know-how and data assets as part of the Validate pillar of Mayo Clinic Platform. Large-scale datasets enable comprehensive and reliable training of AI models to discover and validate clinically relevant software-only biomarkers.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Optellum is an AI lung-health company whose Virtual Nodule Clinic and lung-cancer prediction platform analyze CT imaging for pulmonary nodules — directly comparable to IMVARIA's Bronchosolve product and adjacent to its lung-disease focus.

TypeDirect peer
Description

Aidoc develops clinical AI algorithms that analyze medical imaging across multiple specialties and integrate into radiologist workflows, making it a comparable AI-imaging-diagnostics peer (broader portfolio than IMVARIA but overlapping target customers and use cases).

TypeBroad incumbent
Description

Viz.ai is the leader in AI-powered disease detection and care coordination, and is both a partner of IMVARIA (post-Nov 2025) and a broader AI-imaging incumbent whose pulmonary and radiology workflow tools compete for the same health-system budgets.

TypeDirect peer
Description

Arterys offers cloud-based AI medical imaging analytics with FDA-cleared products across multiple modalities — comparable to IMVARIA as a cloud-delivered AI imaging diagnostics company pursuing similar enterprise health-system customers.

TypeDirect peer
Description

Riverain Technologies develops AI algorithms for chest CT and X-ray analysis with a long-standing focus on lung and thoracic imaging — directly comparable to IMVARIA's Fibresolve and ScreenDx products targeting ILD, IPF, and lung findings.

TypeEmerging player
Description

Anumana is an AI-driven SaMD company developing ECG-based diagnostics for cardiology, backed by Mayo Clinic — comparable to IMVARIA as a physician-engineer-led SaMD commercializing AI diagnostics through FDA pathways and clinical partnerships.

7Tempus Labs
TypeBroad incumbent
Description

Tempus is a large AI-driven precision medicine platform combining clinical and molecular data for diagnostics and biopharma research — broader than IMVARIA but overlapping in the AI diagnostic and biopharma/clinical-trial services business model.

TypeDirect peer
Description

Perspectum develops AI-powered imaging diagnostic services (notably for liver disease) delivered through a centralized digital lab model — directly comparable to IMVARIA's Digital Biomarker Lab model and SaMD commercial approach.

TypeDirect peer
Description

Quibim provides AI-powered medical imaging analysis across multiple organ systems as a SaaS/diagnostics platform for hospitals and clinical trials — overlapping with IMVARIA in AI imaging diagnostics for enterprise health systems and life sciences customers.

TypeEmerging player
Description

Paige builds AI-driven digital diagnostics with FDA-authorized products for pathology and oncology — comparable to IMVARIA as a clinical AI diagnostics company pursuing FDA-authorized SaMD in cancer-adjacent specialties.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IMVARIA

AI Medical Imaging Diagnosticsimvaria.com

IMVARIA is a Berkeley-based SaMD company that uses AI to analyze CT scans and clinical data for non-invasive diagnosis of interstitial lung disease, idiopathic pulmonary fibrosis, and lung cancer, serving pulmonologists, health systems, and biopharma clients through its FDA-authorized Fibresolve, ScreenDx, and investigational Bronchosolve products.

What IMVARIA does

IMVARIA Inc. is a Berkeley, California-based software-as-medical-device (SaMD) company founded in 2019 that commercializes AI-driven digital biomarker diagnostics for serious lung disease. The company operates a centralized, cloud-based Digital Biomarker Lab—functionally analogous to a specialty CLIA lab but analyzing imaging and clinical data rather than biospecimens—where clinicians submit CT scans and clinical information for AI analysis and receive reports within minutes. IMVARIA is ISO 13485 certified and HIPAA compliant, and serves pulmonologists, health systems, life sciences companies, and patients with suspected interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and lung cancer.

The company's product portfolio centers on three AI diagnostic tools. Fibresolve, the lead product, received FDA De Novo marketing authorization in January 2024 as the first FDA-authorized diagnostic of any type in lung fibrosis, and the first Breakthrough-Designated AI diagnostic with simultaneously adopted AMA Category III CPT billing code (0880T). ScreenDx received FDA 510(k) clearance in January 2025 as the first AI technology authorized to assess interstitial lung findings compatible with ILD. Bronchosolve, an investigational non-invasive lung cancer diagnostic, met primary endpoints in the pivotal VIRTUAL-BRONCH study in October 2025 and is advancing toward FDA submission. The underlying platform combines computer vision over CT imaging with multi-modal clinical data (text and structured values) to produce diagnostic subtype classifications and mortality predictions, trained on thousands of tissue-pathology-confirmed cases and augmented by a data collaboration with Mayo Clinic Platform.

IMVARIA generates revenue primarily through transaction-based diagnostic testing fees billable under CPT 0880T, complemented by professional services revenue from biopharma and clinical trial sponsors that use the platform for risk stratification and trial enrollment. Go-to-market combines direct enterprise sales to pulmonologists and health systems, channel partnerships (Medical Horizons for MENA, Viz.ai for U.S. health system distribution), and conference-driven clinical engagement (ATS, CHEST). The company has raised strategic capital from InHealth Ventures, Labcorp Venture Fund, Cedar Crest Holdings, Creative Ventures, and Meridian Street Capital, and was awarded a Phase I NIH SBIR grant to extend the platform into oncology.

IMVARIA firmographics

Firmographics
Name
IMVARIA
Legal name
IMVARIA Inc.
Website
https://imvaria.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
IMVARIA is a Berkeley-based SaMD company that uses AI to analyze CT scans and clinical data for non-invasive diagnosis of interstitial lung disease, idiopathic pulmonary fibrosis, and lung cancer, serving pulmonologists, health systems, and biopharma clients through its FDA-authorized Fibresolve, ScreenDx, and investigational Bronchosolve products.
Ownership category
akta.pro rank

IMVARIA industry classification

Industry
Product category
AI Medical Imaging Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAKANAF
Interstitial Lung Disease (ILD) & Pulmonary Fibrosis Care
SECONDARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
SECONDARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics

Keywords

  • AI diagnostic services
  • Lung disease diagnostics
  • Digital biomarker platform
  • Medical imaging AI
  • Clinical decision support

Where IMVARIA is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices1 record

Markets served

IMVARIA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Diagnostic Testing Services: IMVARIA generates revenue through its AI-powered diagnostic testing services. Clinicians order Fibresolve and ScreenDx tests through IMVARIA's centralized service, submitting CT scans and clinical data for AI analysis. Results are returned to the ordering clinician. The service is billable using Category III CPT code 0880T for test result interpretation, making it practical for clinicians to incorporate into medical practice. The company works with insurance companies and has financial assistance programs for individuals.
  2. Life Sciences / Clinical Trial Services: IMVARIA offers its AI biomarker technology to biopharma partners and clinical trialists for optimizing study enrollment, risk-stratifying patients at trial enrollment, and developing predictions for treatment response. This represents a B2B revenue stream serving the pharmaceutical and clinical research market.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goFibresolve diagnostic test for ILD/IPF assessment

Go-to-market motion4 records

Distribution channels3 records

Marketing channels5 records

IMVARIA product offering

Product offering

Core offering

IMVARIA provides AI-driven digital biomarker diagnostic services that analyze lung CT imaging and clinical data through a centralized cloud-based Digital Biomarker Lab. Its commercial products include Fibresolve (FDA De Novo authorized for adjunctive diagnosis of ILD/IPF), ScreenDx (FDA 510(k) cleared for automated ILD screening), and the investigational Bronchosolve (non-invasive pulmonary nodule/lung cancer assessment). Clinicians and health systems submit cases and receive AI-generated diagnostic subtype classifications in minutes, billable under Category III CPT code 0880T.

Product overview

IMVARIA is a Software-as-Medical-Device (SaMD) company offering AI-driven digital biomarker solutions through a centralized diagnostic service model. The core product portfolio includes three distinct AI diagnostic tools: Fibresolve (FDA De Novo authorized, January 2024) for adjunctive diagnosis of ILD and IPF; ScreenDx (FDA 510(k) cleared, January 2025) for automated ILD screening; and Bronchosolve (investigational, pivotal study completed October 2025) for lung cancer diagnosis in suspicious pulmonary nodules. All products analyze CT imaging data using proprietary machine learning algorithms without requiring invasive procedures. Clinicians access these services through IMVARIA's centralized cloud-based AI Lab by submitting cases via a web order portal, with results returned within minutes. The platform also includes a financial assistance program and Category III CPT billing codes for reimbursement.

Differentiator

Problem solved

Functional benefit

Brands

  • Fibresolve: FDA-authorized AI diagnostic service for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) assessment using non-invasive CT scan analysis
  • ScreenDx
  • Bronchosolve
  • Digital Biomarker Lab

Products and services

  • Fibresolve FDA-authorized AI diagnostic service that uses fully automated machine learning and non-invasive CT scans of the lungs to provide diagnostic subtype classification of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), serving as an adjunct to clinicians prior to invasive testing.
  • ScreenDx FDA 510(k)-cleared AI-powered screening algorithm that automatically assesses CT scans for interstitial lung findings compatible with ILD, operating as a background-only technology to enhance referral workflows without requiring technologist operation.
  • Bronchosolve Investigational AI-powered diagnostic solution for the assessment of suspicious pulmonary nodules and non-invasive lung cancer diagnosis; a fully automated end-to-end platform designed for improved classification of indeterminate lung nodules.
  • AI Lab (Digital Biomarker Lab) Centralized, cloud-based digital lab operating like a specialty CLIA lab but handling data rather than physical samples; clinicians and biopharma clients transmit cases and receive AI analysis reports in minutes, supporting multiple imaging modalities (CT, MRI) and data types under ISO 13485 quality compliance.

Quantifiable outcome

  • IPF diagnoses increased by >3x in challenging ILD and IPF cases in the pre-invasive setting
  • +3 more outcomes

Companies that use IMVARIA

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

IMVARIA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

IMVARIA partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Viz.aicoreTechnology or Integration · 18 November 2025IMVARIA partnered with Viz.ai, the leader in AI-powered disease detection and care coordination, in November 2025. This collaboration expands Viz.ai's pulmonary portfolio and introduces new AI capabilities that can assess for interstitial lung findings compatible with ILD. Viz.ai has existing relationships with health systems using its care coordination software.
  • Medical HorizonscoreChannel Partner/ Reseller/ Distributor · 10 June 2025IMVARIA announced a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy, to expand presence in the MENA (Middle East and North Africa) region. Medical Horizons' extensive sales network and expertise in cloud-based healthcare solutions provides a strong foundation for accelerating adoption of IMVARIA's technology among pulmonologists. The company has a proven track record with installations at renowned centers including Campus Biomedico Roma, Meyer Labs Florence, Sant' Andrea Roma, and Gruppo Multimedia Milano.
  • Mayo CliniccoreStrategic or Co-development Partner · 1 November 2023IMVARIA entered into a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer. The collaboration brings together IMVARIA's engineering expertise in digital biomarkers with Mayo Clinic's know-how and data assets as part of the Validate pillar of Mayo Clinic Platform. Large-scale datasets enable comprehensive and reliable training of AI models to discover and validate clinically relevant software-only biomarkers.

Scale indicators7 records

Recent moves10 records

Expansion highlights7 records

IMVARIA competitors and assessment

Company assessment

Direct peers

  • Optellum: Optellum is an AI lung-health company whose Virtual Nodule Clinic and lung-cancer prediction platform analyze CT imaging for pulmonary nodules — directly comparable to IMVARIA's Bronchosolve product and adjacent to its lung-disease focus.
  • Aidoc: Aidoc develops clinical AI algorithms that analyze medical imaging across multiple specialties and integrate into radiologist workflows, making it a comparable AI-imaging-diagnostics peer (broader portfolio than IMVARIA but overlapping target customers and use cases).
  • Arterys: Arterys offers cloud-based AI medical imaging analytics with FDA-cleared products across multiple modalities — comparable to IMVARIA as a cloud-delivered AI imaging diagnostics company pursuing similar enterprise health-system customers.
  • Riverain Technologies: Riverain Technologies develops AI algorithms for chest CT and X-ray analysis with a long-standing focus on lung and thoracic imaging — directly comparable to IMVARIA's Fibresolve and ScreenDx products targeting ILD, IPF, and lung findings.
  • Perspectum: Perspectum develops AI-powered imaging diagnostic services (notably for liver disease) delivered through a centralized digital lab model — directly comparable to IMVARIA's Digital Biomarker Lab model and SaMD commercial approach.
  • Quibim: Quibim provides AI-powered medical imaging analysis across multiple organ systems as a SaaS/diagnostics platform for hospitals and clinical trials — overlapping with IMVARIA in AI imaging diagnostics for enterprise health systems and life sciences customers.

Broad incumbents

  • Viz.ai: Viz.ai is the leader in AI-powered disease detection and care coordination, and is both a partner of IMVARIA (post-Nov 2025) and a broader AI-imaging incumbent whose pulmonary and radiology workflow tools compete for the same health-system budgets.
  • Tempus Labs: Tempus is a large AI-driven precision medicine platform combining clinical and molecular data for diagnostics and biopharma research — broader than IMVARIA but overlapping in the AI diagnostic and biopharma/clinical-trial services business model.

Emerging players

  • Anumana: Anumana is an AI-driven SaMD company developing ECG-based diagnostics for cardiology, backed by Mayo Clinic — comparable to IMVARIA as a physician-engineer-led SaMD commercializing AI diagnostics through FDA pathways and clinical partnerships.
  • Paige.AI: Paige builds AI-driven digital diagnostics with FDA-authorized products for pathology and oncology — comparable to IMVARIA as a clinical AI diagnostics company pursuing FDA-authorized SaMD in cancer-adjacent specialties.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

IMVARIA social profiles

Digital presence

IMVARIA compliance and trust

Trust signal

Compliance2 records

IMVARIA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IMVARIA leadership team

Management profile

Number of profiles

Profiles3 records

IMVARIA funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IMVARIA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMVARIA

What does IMVARIA do?

IMVARIA provides AI-driven digital biomarker diagnostic services that analyze lung CT imaging and clinical data through a centralized cloud-based Digital Biomarker Lab. Its commercial products include Fibresolve (FDA De Novo authorized for adjunctive diagnosis of ILD/IPF), ScreenDx (FDA 510(k) cleared for automated ILD screening), and the investigational Bronchosolve (non-invasive pulmonary nodule/lung cancer assessment). Clinicians and health systems submit cases and receive AI-generated diagnostic subtype classifications in minutes, billable under Category III CPT code 0880T.

Is IMVARIA a public or private company?

IMVARIA is a private company. It is classified as venture growth investor backed and is currently operating.

When was IMVARIA founded?

IMVARIA was founded in 2019. It employs 1 to 10 people.

Where is IMVARIA based?

IMVARIA is headquartered in Berkeley, United States, in the North America region.

How does IMVARIA make money?

Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are life Sciences / Clinical Trial Services.

Who are IMVARIA's main competitors?

Direct peers on record are Optellum, Aidoc, Arterys, Riverain Technologies, Perspectum and Quibim. Broad incumbents are Viz.ai and Tempus Labs. Emerging players are Anumana and Paige.AI.

Does IMVARIA have an API?

No public API is recorded for IMVARIA.

What industry is IMVARIA in?

IMVARIA's product category is AI Medical Imaging Diagnostics. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VizUnlocking the Potential of AI in Lung Disease Diagnosis, Management, and Care CoordinationToby Emanuel, Director of Life Science Innovation at Viz.ai, argues that AI-powered care coordination software has significant potential to transform lung disease management across three key areas: enhanced detection and diagnosis, streamlined care coordination, and personalized treatment aligned with clinical guidelines. The article cites internal data showing Viz.ai's pulmonary embolism solution achieved a 98% reduction in time to assessment and a 74% decrease in in-hospital mortality, while also referencing collaborations with Sanofi, Regeneron, and IMVARIA as examples of AI partnerships expanding chronic lung disease care. The author posits that as health systems increasingly integrate AI, these tools can reduce information overload for clinicians and enable more timely, evidence-based patient care.Healthcare IT TodayIMVARIA Announces Strategic InvestmentsIMVARIA announced strategic investments from InHealth Ventures, Labcorp Venture Fund, and Cedar Crest Holdings to accelerate growth and innovation in AI-driven digital healthcare, with a focus on lung disease diagnostics. Separately, Canopy raised $22 million in Series B funding to expand its connected safety and location intelligence platform for healthcare workers in the U.S.Pulse 2.0IMVARIA Announces Strategic Investments For AI-Based Digital Biomarker SolutionsIMVARIA, a Berkeley-based health tech company developing AI-driven digital biomarker solutions, announced strategic investments from InHealth Ventures, Labcorp Venture Fund, and Cedar Crest Holdings to accelerate growth and expand its AI-powered diagnostic services for lung diseases. The funding will support the company's flagship product Fibresolve, which received FDA authorization in early 2024 for use in suspected interstitial lung disease, including idiopathic pulmonary fibrosis. The company also recently received a Phase I Small Business Innovation Research grant from the National Institutes of Health to develop a new test for malignancy assessment in chest CT scans.FinSMEsIMVARIA Raises FundingIMVARIA, a Berkeley-based health tech company, raised an undisclosed amount in funding led by InHealth Ventures with participation from Labcorp Venture Fund and Cedar Crest Holdings. The company will use the funds to extend its AI-driven diagnostic services for lung disease and make tests accessible to clinicians, especially pulmonologists.VC News DailyIMVARIA Nets Strategic InvestmentsIMVARIA, a health tech company specializing in AI-driven digital biomarker solutions, announced strategic investments from new and existing investors to accelerate its growth and innovation in digital healthcare. InHealth Ventures led the funding round, with participation from the Labcorp Venture Fund and existing partner Cedar Crest Holdings. The capital will enable IMVARIA to expand its AI-driven diagnostic services for lung disease and improve accessibility for clinicians, particularly pulmonologists.Business Wire BlogIMVARIA’s AI-Powered, Non-Invasive Bronchosolve Solution Meets Primary Endpoints for Lung Cancer Diagnosis in Pivotal VIRTUAL-BRONCH StudyIMVARIA Inc. announced that its AI-powered diagnostic solution Bronchosolve met primary endpoints in the pivotal VIRTUAL-BRONCH Study, demonstrating improved accuracy in non-invasive lung cancer diagnosis from suspicious pulmonary nodules compared to standard clinical assessments. The study analyzed cases from patients at multiple major cancer centers and health systems in the U.S., with key results to be presented at a future scientific conference in 2026. The company is building on the success of its existing FDA-authorized Fibresolve diagnostic service for pulmonary fibrosis, which is currently used by more than 30 medical institutions across the U.S.YahooIMVARIA Awarded Phase I NIH SBIR Grant to Extend the Company’s AI-powered Adjunctive Diagnostic Service into OncologyIMVARIA Inc., a health tech company, has been awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health to develop an AI-powered test for malignancy assessment in chest CTs. The grant expands IMVARIA's FDA-authorized AI platform beyond lung disease diagnostics into oncology for the first time as a company. IMVARIA has already presented preliminary results and will use the funding to advance the technology to regulatory-grade performance for eventual clinical use alongside its existing FDA-authorized diagnostic services.Respiratory TherapyFDA Clears AI-Powered Idiopathic Pulmonary Fibrosis DiagnosticThe US FDA granted De Novo marketing authorization for Fibresolve, an AI-powered digital biomarker developed by Imvaria to assist in diagnosing idiopathic pulmonary fibrosis. Concurrently, Imvaria announced the acquisition of CPT billing codes from the American Medical Association, enabling the tool to be billed by clinicians.